An email has been sent to your address with instructions for changing your password.
There is no user registered with this email.
Sign Up
To create a free account, please fill out the form below.
Thank you for signing up!
A confirmation email has been sent to your email address. Please check your email and follow the instructions in the message to complete the registration process. If you do not receive the email, please check your spam folder or contact us for assistance.
Welcome to our platform!
Oops!
Something went wrong while trying to create your new account. Please try again and if the problem persist, Email Us to receive support.
GlycoMimetics to Present at Two Upcoming Healthcare Investor Conferences
Rhea-AI Impact
(Low)
Rhea-AI Sentiment
(Neutral)
Tags
conferences
Rhea-AI Summary
GlycoMimetics, Inc. (Nasdaq: GLYC) announces that CEO Harout Semerjian will present at two upcoming healthcare conferences. The Stifel 2021 Virtual Healthcare Conference will take place on November 15, with GlycoMimetics presenting at 3:20 p.m. ET. The Jefferies London Healthcare Conference is scheduled for November 17, with the presentation at 11:20 AM GMT (6:20 AM ET). GlycoMimetics focuses on developing glycobiology-based therapies for cancers and inflammatory diseases, advancing its drug pipeline located in Rockville, MD.
Positive
None.
Negative
None.
ROCKVILLE, Md.--(BUSINESS WIRE)--
GlycoMimetics, Inc. (Nasdaq: GLYC), today announces that Chief Executive Officer Harout Semerjian will present an overview of the company at the upcoming Stifel 2021 Virtual Healthcare Conference on Monday, November 15 and the Jefferies London Healthcare Conference on Wednesday, November 17. Both presentations will be available on the Company’s website, under the Investors tab. Details are as follows:
Stifel 2020 Virtual Healthcare Conference November 15-17, 2021 GlycoMimetics presentation: Monday, November 15, 3:20 p.m. (ET)
Jefferies London Healthcare Conference November 16-19, 2021 GlycoMimetics presentation: Wednesday, November 17, 11:20 AM GMT (6:20 AM ET)
About GlycoMimetics, Inc.
GlycoMimetics is a clinical-stage biotechnology company discovering and developing glycobiology-based therapies for cancers, including acute myeloid leukemia (AML), and for inflammatory diseases with high unmet need. The Company’s science is based on an understanding of the role that carbohydrates play on the surface of every living cell and applying its specialized chemistry platform to discover small molecule drugs, known as glycomimetics, which alter these carbohydrate-mediated pathways in a variety of disease states, including signaling in cancer and inflammation. As a leader in this space, GlycoMimetics is leveraging this unique targeted approach to advance its pipeline of wholly owned drug candidates, with the goal of developing transformative therapies for serious diseases. GlycoMimetics is located in Rockville, MD in the BioHealth Capital Region. Learn more at www.glycomimetics.com.
